Skip to main content

Table 1 Clinicopathological characteristics of mucinous epithelial ovarian cancer patients in training and validation cohorts

From: Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery

Variable

Training cohort

[n(%)]

Internal validation cohort [n(%)]

External validation cohort [n(%)]

P-value

Age (yrs)

   

0.006

 ≤ 50

255 (44.6%)

115 (46.7%)

108 (58.1%)

 

 > 50

317 (55.4%)

131 (53.3%)

78 (41.9%)

 

Marital status

   

< 0.001

 Married

270 (47.2%)

116 (47.2%)

161 (86.6%)

 

 Other conditions

302 (52.8%)

130 (52.8%)

25 (13.4%)

 

Differentiation

   

0.217

 Well

258 (45.1%)

107 (43.5%)

77 (41.4%)

 

 Moderately

234 (40.9%)

104 (42.3%)

70 (37.6%)

 

 Poorly

80 (14.0%)

35 (14.2%)

39 (21.0%)

 

Tumor stage

   

< 0.001

 IA-IB/ Localized

338 (59.1%)

148 (60.8%)

31 (16.7%)

 

 IC-IIB/ Regional

155 (27.1%)

64 (26.0%)

87 (46.8%)

 

 III-IV/ Distant

79 (13.8%)

34 (13.8%)

68 (36.6%)

 

CA125

   

0.011

 Negative/Unknown

282 (49.3%)

121 (49.2%)

69 (37.1%)

 

 Positive

290 (50.7%)

125 (50.8%)

117 (62.9%)

 

LNM

   

0.105

 No/No resection

556 (97.2%)

234 (95.1%)

175 (94.1%)

 

 Positive

16 (2.8%)

12 (4.9%)

11 (5.9%)

 

Residual Disease

   

< 0.001

 R0

517 (90.4%)

225 (91.5%)

129 (69.4%)

 

 R1

29 (5.1%)

11 (4.5%)

22 (11.8%)

 

 R2

26 (4.5%)

10 (4.1%)

35 (18.8%)

 

Total

572 (100%)

246 (100%)

186 (100%)

 
  1. LNM lymph node metastasis, R0 no residual disease, R1 residual disease < 1 cm, R2 residual disease ≥ 1 cm